雄激素受体表达在转移性三阴性乳腺癌患者中的预后作用。

Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer.

机构信息

National Cancer Institute, Kyiv 03022, Ukraine.

出版信息

Exp Oncol. 2020 Jun;42(2):140-143. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14579.

DOI:10.32471/exp-oncology.2312-8852.vol-42-no-2.14579

PMID:32602289

Abstract

UNLABELLED

At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate.

AIM

To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC.

MATERIALS AND METHODS

The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC.

RESULTS

The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05).

CONCLUSIONS

The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients.

摘要

目前，三阴性乳腺癌（TNBC）患者除了肿瘤大小、淋巴结状态、分化程度和增殖率等已知的临床因素外，没有有效的预后生物标志物。

目的

评估雄激素受体（AR）表达在 TNBC 患者中的预后作用。

材料和方法

评估了 116 例转移性 TNBC 患者肿瘤组织中 AR 表达水平对总生存期的影响，根据肿瘤的临床、组织学和免疫组织化学特征进行评估。

结果

显示 AR 表达在不同分期的 TNBC 患者中的独立预后价值。与 AR 阴性肿瘤相比，AR 阳性肿瘤患者的中位总生存期更高（57 个月比 27 个月，p < 0.0001）。AR 阳性 TNBC 组的 5 年生存率为 47.6 ± 8.3%，而 AR 阴性 TNBC 组为 20.0 ± 5.3%（p < 0.05）。